Baseline characteristics of patients with diffuse large B-cell lymphoma according to EBV-encoded RNA-1 (EBER) status
| Characteristics and parameters . | All patients . | EBER+ . | EBER− . | P . |
|---|---|---|---|---|
| Total cases, no. (%) | 380 (100) | 34 (9.0) | 346 (91.0) | |
| Median age, y (range) | 56 (18–95) | 65 (20–95) | 56 (18–89) | .009 |
| Age, no. (%) | ||||
| 60 y or less | 241 (63.4) | 14 (41.2) | 227 (65.6) | .005 |
| Older than 60 y | 139 (36.6) | 20 (58.8) | 119 (34.4) | |
| Sex, no. (%) | ||||
| Male | 221 (58.2) | 18 (52.9) | 203 (58.7) | .518 |
| Female | 159 (41.8) | 16 (47.1) | 143 (41.3) | |
| Performance status, no. (%) | ||||
| ECOG 0–1* | 293 (80.1) | 24 (70.6) | 269 (81.0) | .147 |
| ECOG 2–4 | 73 (19.9) | 10 (29.4) | 63 (19.0) | |
| Initial presentation, no. (%) | ||||
| Nodal | 96 (25.3) | 9 (26.5) | 87 (26.1) | .339 |
| Extranodal | 100 (26.3) | 6 (17.6) | 94 (28.2) | |
| Nodal and extranodal | 171 (45.0) | 19 (55.9) | 152 (45.6) | |
| Ann Arbor stage, no. (%) | ||||
| Limited, I-II | 254 (66.8) | 14 (42.4) | 240 (72.1) | <.001 |
| Advanced, III-IV | 112 (29.5) | 19 (57.6) | 93 (27.9) | |
| No. of extranodal involvement, no. (%) | ||||
| 0 or 1 | 312 (82.1) | 23 (67.6) | 289 (83.5) | .009 |
| 2 or more | 58 (15.3) | 11 (32.4) | 47 (13.6) | |
| Lactic dehydrogenase, no. (%) | ||||
| Upper limit of normal or below | 203 (56.2) | 20 (60.6) | 183 (55.8) | .071 |
| Over the upper limit of normal | 158 (43.8) | 13 (39.4) | 145 (44.2) | |
| International Prognostic Index risk groups, no. (%) | ||||
| Low/low intermediate | 279 (73.4) | 20 (62.5) | 259 (79.9) | .015 |
| High intermediate/high | 77 (20.3) | 12 (37.5) | 65 (20.1) | |
| B symptom, no. (%) | ||||
| Positive | 74 (20.4) | 13 (39.4) | 61 (18.5) | .004 |
| Negative | 289 (79.6) | 20 (60.6) | 269 (81.5) | |
| Bone marrow involvement, no. (%) | ||||
| Positive | 74 (20.4) | 13 (39.4) | 61 (18.5) | .104 |
| Negative | 289 (79.6) | 20 (60.6) | 269 (81.5) | |
| Primary treatment, no. (%) | ||||
| Anthracycline-based chemotherapy with or without radiotherapy | 224 (58.9) | 25 (73.5) | 199 (57.5) | |
| Rituximab with cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy with or without radiotherapy | 63 (16.6) | 2 (5.9) | 61 (17.6) | .825* |
| Nonanthracycline-based chemotherapy | 45 (11.8) | 3 (8.8) | 42 (12.1) | |
| Best supportive care only | 48 (12.6) | 4 (11.8) | 44 (12.7) | |
| Response to front-line, no. (%) | ||||
| Chemotherapy, n = 232† | ||||
| Complete remission or partial remission | 209 (90.1) | 18 (72.0) | 191 (92.3) | .006 |
| Stable disease or progressive disease | 23 (9.9) | 7 (28.0) | 16 (7.7) | |
| Histologic subtype, no. (%); n = 296 | ||||
| Germinal center B cell–like | 125 (42.2) | 6 (28.6) | 119 (34.4) | .253 |
| Nongerminal center B cell–like | 171 (57.8) | 15 (71.4) | 156 (45.1) |
| Characteristics and parameters . | All patients . | EBER+ . | EBER− . | P . |
|---|---|---|---|---|
| Total cases, no. (%) | 380 (100) | 34 (9.0) | 346 (91.0) | |
| Median age, y (range) | 56 (18–95) | 65 (20–95) | 56 (18–89) | .009 |
| Age, no. (%) | ||||
| 60 y or less | 241 (63.4) | 14 (41.2) | 227 (65.6) | .005 |
| Older than 60 y | 139 (36.6) | 20 (58.8) | 119 (34.4) | |
| Sex, no. (%) | ||||
| Male | 221 (58.2) | 18 (52.9) | 203 (58.7) | .518 |
| Female | 159 (41.8) | 16 (47.1) | 143 (41.3) | |
| Performance status, no. (%) | ||||
| ECOG 0–1* | 293 (80.1) | 24 (70.6) | 269 (81.0) | .147 |
| ECOG 2–4 | 73 (19.9) | 10 (29.4) | 63 (19.0) | |
| Initial presentation, no. (%) | ||||
| Nodal | 96 (25.3) | 9 (26.5) | 87 (26.1) | .339 |
| Extranodal | 100 (26.3) | 6 (17.6) | 94 (28.2) | |
| Nodal and extranodal | 171 (45.0) | 19 (55.9) | 152 (45.6) | |
| Ann Arbor stage, no. (%) | ||||
| Limited, I-II | 254 (66.8) | 14 (42.4) | 240 (72.1) | <.001 |
| Advanced, III-IV | 112 (29.5) | 19 (57.6) | 93 (27.9) | |
| No. of extranodal involvement, no. (%) | ||||
| 0 or 1 | 312 (82.1) | 23 (67.6) | 289 (83.5) | .009 |
| 2 or more | 58 (15.3) | 11 (32.4) | 47 (13.6) | |
| Lactic dehydrogenase, no. (%) | ||||
| Upper limit of normal or below | 203 (56.2) | 20 (60.6) | 183 (55.8) | .071 |
| Over the upper limit of normal | 158 (43.8) | 13 (39.4) | 145 (44.2) | |
| International Prognostic Index risk groups, no. (%) | ||||
| Low/low intermediate | 279 (73.4) | 20 (62.5) | 259 (79.9) | .015 |
| High intermediate/high | 77 (20.3) | 12 (37.5) | 65 (20.1) | |
| B symptom, no. (%) | ||||
| Positive | 74 (20.4) | 13 (39.4) | 61 (18.5) | .004 |
| Negative | 289 (79.6) | 20 (60.6) | 269 (81.5) | |
| Bone marrow involvement, no. (%) | ||||
| Positive | 74 (20.4) | 13 (39.4) | 61 (18.5) | .104 |
| Negative | 289 (79.6) | 20 (60.6) | 269 (81.5) | |
| Primary treatment, no. (%) | ||||
| Anthracycline-based chemotherapy with or without radiotherapy | 224 (58.9) | 25 (73.5) | 199 (57.5) | |
| Rituximab with cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy with or without radiotherapy | 63 (16.6) | 2 (5.9) | 61 (17.6) | .825* |
| Nonanthracycline-based chemotherapy | 45 (11.8) | 3 (8.8) | 42 (12.1) | |
| Best supportive care only | 48 (12.6) | 4 (11.8) | 44 (12.7) | |
| Response to front-line, no. (%) | ||||
| Chemotherapy, n = 232† | ||||
| Complete remission or partial remission | 209 (90.1) | 18 (72.0) | 191 (92.3) | .006 |
| Stable disease or progressive disease | 23 (9.9) | 7 (28.0) | 16 (7.7) | |
| Histologic subtype, no. (%); n = 296 | ||||
| Germinal center B cell–like | 125 (42.2) | 6 (28.6) | 119 (34.4) | .253 |
| Nongerminal center B cell–like | 171 (57.8) | 15 (71.4) | 156 (45.1) |
Data were missing as follows: performance status (n = 14), initial disease presentation (n = 13), Ann Arbor stage (n = 14), lactic dehydrogenase level (n = 19), no. of extranodal involvement (n = 10), International Prognostic Index score (n = 24), B symptoms (n = 17), bone marrow involvement (n = 15), and histologic subtype (n = 84).
ECOG indicates Eastern Cooperative Oncology Group.
Two hundred forty-three patients received chemotherapy as a front-line treatment and 232 patients were assessable for response.